Literature DB >> 20051285

The association of antiphospholipid antibodies with pregnancy-related first time venous thrombosis--a population-based case-control study.

A Bergrem1, E M Jacobsen, F E Skjeldestad, A F Jacobsen, M Skogstad, P M Sandset.   

Abstract

In this population-based case-control study we explored the association of antiphospholipid antibodies with pregnancy-related venous thrombosis. From 1990 through 2003 615 pregnant women were identified at 18 hospitals in Norway with a diagnosis of first time VT. In 2006, 531 of 559 eligible cases and 1092 of 1229 eligible controls were invited for further investigations. The final study population comprised 313 cases and 353 controls, who completed a comprehensive questionnaire and donated a single blood sample, 3-16 years after index pregnancy. We report the results on lupus anticoagulant, anticardiolipin antibodies, and anti-ss(2) glycoprotein-1 antibodies alone, in combination, and with the contribution of the factor V Leiden and the prothrombin gene G20210A polymorphisms. Cut-off values for APAs were chosen according to current international consensus. 29 (9.3%) of the cases and 24 (6.8%) of the controls had at least one positive test for APAs (OR 1.4; 95% CI 0.8-2.5). Nine cases (2.8%) and no controls had more than one positive test (multi-positivity) for APAs. After excluding women with factor V Leiden or prothrombin polymorphisms, still 6 cases were multi-positive for APAs. We conclude that multi-positivity, but not single-positivity, for APAs was weakly associated with a history of ante- and postnatal VT. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20051285     DOI: 10.1016/j.thromres.2009.12.006

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Preventing venous thromboembolism during pregnancy and postpartum: crossing the threshold.

Authors:  Leslie Skeith
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

3.  Long-term impact of intrauterine fetal death on quality of life and depression: a case-control study.

Authors:  Ida Kathrine Gravensteen; Linda Bjørk Helgadottir; Eva-Marie Jacobsen; Per Morten Sandset; Øivind Ekeberg
Journal:  BMC Pregnancy Childbirth       Date:  2012-06-07       Impact factor: 3.007

4.  Long-term impact of pregnancy-related venous thrombosis on quality-of-life, general health and functioning: results of a cross-sectional, case-control study.

Authors:  Hilde Skuterud Wik; Anne Flem Jacobsen; L Sandvik; P M Sandset
Journal:  BMJ Open       Date:  2012-11-08       Impact factor: 2.692

5.  Guidance for the treatment and prevention of obstetric-associated venous thromboembolism.

Authors:  Shannon M Bates; Saskia Middeldorp; Marc Rodger; Andra H James; Ian Greer
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

6.  Genome-wide analysis of genetic determinants of circulating factor VII-activating protease (FSAP) activity.

Authors:  M Olsson; T M Stanne; A Pedersen; E Lorentzen; E Kara; A Martinez-Palacian; N P Rønnow Sand; A F Jacobsen; P M Sandset; J J Sidelmann; G Engström; O Melander; S M Kanse; C Jern
Journal:  J Thromb Haemost       Date:  2018-08-24       Impact factor: 5.824

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.